This study was performed to clarify which titers of a pre-existing antibody could be efficiently boosted by vaccination and to assess the persistence of the antibodies. Two hundred healthy volunteer students with HI antibody titers of ≤1 : 32 were enrolled. There were 6~16% of subjects with the negative HI antibody who had B-cell memory against rubella, because the EIA-IgM antibody remained negative and/or the avidity of the EIA-IgG antibody was high after vaccination. Furthermore most of them had already been vaccinated just once before. The ratio of those in whom the antibody levels increased significantly at one month after vaccination were 98%, 87%, 67% and 32% in subjects with an HI antibody titer of <1 : 8, ≤1:8, ≤1 : 16 and ≤1 : 32 at pre-vaccination, respectively. The titers decreased significantly at two years after vaccination, however the ratio of decrease under each original level being 4%, 21.9%, 42.6% and 73.5% in each group of <1 : 8, ≤1:8,≤1 : 16 and ≤1 : 32, respectively. In comparison with the numbers of the subjects with <1:8, the ones with ≤1:8, ≤1 : 16 and ≤1 : 32 increased 1.5-, 2.5- and 4.7-fold, respectively. Therefore, the recommendation of an HI antibody titer ≤1 : 16 for vaccination in Japan is thought to be loose, although this is to decrease the risk of congenital rubella syndrome. We think that a new assay for cellular immunity for rubella should be developed in the future in order to ascertain whether congenital rubella syndrome will be prevented or not.
View full abstract